Location of Repository

ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma

By Fabrizio Tabbó, Antonella Barreca, Roberto Piva and Giorgio Inghirami

Abstract

The discovery by Morris et al. (1994) of the genes contributing to the t(2;5)(p23;q35) translocation has laid the foundation for a molecular based recognition of anaplastic large cell lymphoma and highlighted the need for a further stratification of T-cell neoplasia. Likewise the detection of anaplastic lymphoma kinase (ALK) genetic lesions among many human cancers has defined unique subsets of cancer patients, providing new opportunities for innovative therapeutic interventions. The objective of this review is to appraise the molecular mechanisms driving ALK-mediated transformation, and to maintain the neoplastic phenotype. The understanding of these events will allow the design and implementation of novel tailored strategies for a well-defined subset of cancer patients

Topics: Oncology
Publisher: Frontiers Research Foundation
OAI identifier: oai:pubmedcentral.nih.gov:3355932
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2003). A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation.Am.J.Surg.Pathol.27,
    2. (2008). A mouse model for EML4-ALK-positive lung cancer.
    3. (1999). A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation.
    4. (2000). A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma.
    5. (2011). A novel KIF5B-ALK variant in nonsmall cell lung cancer.
    6. (2009). A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
    7. (2012). accepted: 10
    8. (2003). ALK a novel lymphomaassociated tumor antigen for vaccination strategies.
    9. (2003). ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma.
    10. (2012). ALK signaling and therapy
    11. (2008). ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
    12. (2003). ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor.
    13. (2010). ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica 95,509–513.
    14. (1998). ALK-positive lymphoma:a single disease with a broad spectrum of morphology.
    15. (2003). ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases.
    16. (1999). ALK+ lymphoma: clinicopathological findings and outcome.
    17. (2001). Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology.
    18. (2002). Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.
    19. (2006). Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplasticlarge-celllymphomacells.
    20. (2012). Anaplastic lymphoma kinase and leukocyte tyrosine kinase: functions and genetic interactions in learning, memory and adult neurogenesis.
    21. (2007). Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor proteintyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation.
    22. (2001). Anaplastic lymphoma kinase proteins and malignancy.
    23. (2011). Anaplastic lymphoma kinase spares organ growth during nutrient restriction in Drosophila.
    24. (2012). and www.frontiersin.org
    25. andSalekdeh,G.H.(2006).Identifi-cation of squamous cell carcinoma associated proteins by proteomics andlossofbetatropomyosinexpression in esophageal cancer.
    26. (2000). ATICALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrentcrypticchromosomalinversion, inv(2)(p23q35).
    27. C.,andHallberg,B.(2009).Anaplastic lymphoma kinase: signalling in development and disease.
    28. (2000). CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.
    29. (2007). CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma.
    30. (2012). CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental modelsofhumancancers.Mol.Cancer Ther.
    31. (1996). Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5).
    32. (1998). Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: infrequent detection of the t(2;5) in extranodal lymphomas.
    33. (2012). Combined effect of ALK and MEK inhibitors in EML4-ALKpositive non-small-cell lung cancer cells.
    34. (1999). Complexvarianttranslocationt(1;2)with TPM3-ALK fusion due to cryptic ALKgenerearrangementinanaplastic large-cell lymphoma.
    35. (2011). Cytogenetically complexSEC31A-ALKfusionsarerecurrent in ALK-positive large Bcell lymphomas.
    36. (2007). Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
    37. (1994). Diagnosis of t(2;5)(p23;q35)-associated Ki1 lymphoma with immunohistochemistry.
    38. (2004). Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasionpropertiesof NIH3T3cells.
    39. (2005). Differential expression of cyclin D3 in ALK+ and ALK- anaplastic large cell lymphoma.
    40. (2012). Discovery of ALK-PTPN3 gene fusion fromhumannon-smallcelllungcarcinoma cell line using next generation RNA sequencing.
    41. (2002). Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity.
    42. (2008). EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
    43. (2008). enhances thetherapeuticeffectsofchemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.
    44. (2011). Epithelioid inflammatory myofibroblastic sarcoma:anaggressiveintra-abdominal variant of inflammatory myofibroblastictumorwithnuclearmembrane or perinuclear ALK.
    45. (2009). Exon array profiling detects EML4-ALK fusion in breast,colorectal,and non-small cell lung cancers.
    46. (2012). Frontiers in Oncology | Cancer MolecularTargets andTherapeutics
    47. (2006). Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.
    48. (2000). Further demonstration of the diversity of chromosomal changes involving 2p23 inALKpositive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like).
    49. (1994). Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM,innon-Hodgkin’slymphoma.
    50. (2003). Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor.
    51. (2001). Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor.
    52. Fusion of the SEC31L1 and ALK genes in an inflammatory myofi-broblastic tumor.
    53. (2010). Gene expression profilinguncoversmolecularclassifiersfor the recognition of anaplastic largecell lymphoma within peripheral Tcell neoplasms.
    54. (2004). Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations.
    55. (2008). Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas.
    56. (2007). Global survey of phosphotyrosinesignalingidentifiesoncogenickinasesinlungcancer.
    57. (2007). Humanized mice in translational biomedical research.
    58. (2009). Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.
    59. (2011). Identification of a novel fusion, SQSTM1-ALK, in ALKpositive large B-cell lymphoma.
    60. (2012). Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
    61. (2002). Identification of novel fusion partners of ALK,the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.
    62. (2007). Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer.
    63. (2003). IdentificationofCARS-ALKfusioninprimary and metastatic lesions of an inflammatory myofibroblastic tumor.
    64. (2009). IGF-IR tyrosinekinaseinteractswithNPM-ALK oncogene to induce survival of Tcell ALK+ anaplastic large-cell lymphoma cells.
    65. (2000). Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma.
    66. (2004). inducesapoptosisandG(1)cellcycle arrest in ALK-positive anaplastic large cell lymphoma.
    67. Inghirami G and The European TCellLymphomaStudyGroup(2012)ALK signalingandtargettherapyinanaplastic large cell lymphoma.
    68. (2010). Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALKfusiononcogene.Cancer Res.
    69. (2003). Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma.
    70. (2011). Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.
    71. (2008). International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings andclinicaloutcomes.J.Clin.Oncol.
    72. (2010). Involvement of Grb2 adaptor protein in nucleophosminanaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.
    73. (2005). JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and Reed-Sternberg cells of Hodgkin lymphoma.
    74. (2009). KIF5B-ALK, a novel fusion oncokinase identified byanimmunohistochemistry-based diagnostic system for ALK-positive lung cancer.
    75. (2012). KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embeddedtissueonly.PLoS
    76. L.,and Pulford,K.(2006).BandCTLresponses to the ALK protein in patients with ALK-positive ALCL.
    77. (2000). large-celllymphomainducesconstitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.
    78. (2002). Model of inhibition of the NPM-ALK kinase activity by herbimycin A. Clin. Cancer Res.
    79. (2001). Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma.
    80. (2002). Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/nullcell lymphoma.
    81. (2005). NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry.
    82. (2003). Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma.
    83. (2011). NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALKpositive, anaplastic large cell lymphoma.
    84. (2004). NPM-ALK fusion kinase of anaplastic largecell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a.
    85. (2009). NPM-ALK oncogenic tyrosinekinasecontrolsT-cellidentityby transcriptional regulation and epigenetic silencing in lymphoma cells.
    86. (2011). NPM-ALK signals through glycogen synthase kinase 3beta to promote oncogenesis. Oncogene.d o i :
    87. (2003). NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.
    88. (2007). NPM/ALK-positive anaplastic large cell lymphoma.
    89. (2000). Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway.
    90. (1998). Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity.
    91. (2004). Nucleophosmin-anaplastic lymphomakinaseofanaplasticlarge-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.
    92. (2011). Oncogenic kinase NPM/ALK induces expression of HIF1alpha mRNA.
    93. (2007). Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    94. (2007). Pleiotrophinisaneurotrophicfactor forspinalmotorneurons.Proc.Natl.
    95. (1997). Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome.
    96. (2007). Proteomic profiling of proteins dysregulated in Chinese esophageal squamous cell carcinoma.J.Mol.Med.85,863–875.
    97. (2007). RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors.
    98. (2011). Renal cell carcinoma with novel VCL-ALKfusion:newrepresentative of ALK-associated tumor spectrum.
    99. (2012). RET, ROS1 and ALK fusions in lung cancer.
    100. (1997). Retrovirus-mediated gene transfer of NPM-ALK causes lymphoidmalignancyinmice.Blood 90,
    101. (2011). Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.
    102. (2001). Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinasemediated lymphomagenesis.
    103. (2006). SHP1 tyrosine phosphatase negativelyregulatesNPM-ALKtyrosine kinase signaling.
    104. (2005). Stat3 is required for ALK-mediated lymphomagenesisandprovidesapossibletherapeutic target.
    105. (2009). STAT3 revs up the powerhouse.
    106. (2006). STAT3: a multifaceted oncogene.
    107. (2007). STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression.
    108. (2008). Targeting Bcl-2 family proteins modulates thesensitivityofB-celllymphomato rituximab-induced apoptosis.
    109. (2008). The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.
    110. (2008). The anaplastic lymphoma kinase in the pathogenesis of cancer.
    111. (2008). The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.
    112. (2008). The BH3-only mimetic ABT-737synergizestheantineoplastic activity of proteasome inhibitors in lymphoid malignancies.
    113. (2009). The enzymatic activity of 5-aminoimidazole4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL.
    114. (2006). The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated J u n Bl e v e li nac e l lt y p e -specific manner.
    115. (2011). The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRbdependent tumor-suppressive pathway.
    116. (2007). The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
    117. (2008). The structure and functions of NPM1/Nucleophsmin/B23, a multifunctional nucleolar acidic protein.
    118. (2011). Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboringthefusiononcogeneEML4-ALK.
    119. (2000). TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.
    120. (1999). TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations.
    121. (2004). Ubiquitination and proteasomal degradation of nucleophosminanaplastic lymphoma kinase induced by 17-allylaminodemethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein.
    122. (2005). What have we learnt from mouse models of NPMALK-induced lymphomagenesis?

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.